Literature DB >> 16041018

Intranasal delivery of group B meningococcal native outer membrane vesicle vaccine induces local mucosal and serum bactericidal antibody responses in rabbits.

David R Shoemaker1, Nancy B Saunders, Brenda L Brandt, E Ellen Moran, Andrew D Laclair, Wendell D Zollinger.   

Abstract

We have previously shown that intranasal immunization of mice with meningococcal native outer membrane vesicles (NOMV) induces both a good local mucosal antibody response and a good systemic bactericidal antibody response. However, in the intranasal mouse model, some of the NOMV entered the lung and caused an acute granulocytic response. We therefore developed an alternate animal model using the rabbit. This model reduces the probability of lung involvement and more closely mimics intranasal immunization of humans. Rabbits immunized intranasally with doses of 100 mug of NOMV in 0.5 ml of saline developed serum bactericidal antibody levels comparable to those of rabbits immunized intramuscularly with 25-mug doses, particularly when the primary intranasal immunization was given daily for 3 days. Intranasal immunization also induced a local mucosal response as evidenced by immunoglobulin A antibody in saliva, nasal washes, and lung lavage fluids. NOMV from a capsule-deficient mutant induced higher serum bactericidal antibody responses than NOMV from the encapsulated parent. Meningococcal NOMV could be administered intranasally at 400 mug with no pyrogenic activity, but as little as 0.03 mug/kg of body weight administered intravenously or 25 mug administered intramuscularly induced a pyrogenic response. These data indicate that the rabbit is a useful model for preclinical testing of intranasal meningococcal NOMV vaccines, and this immunization regimen produces a safe and substantial systemic and local mucosal antibody response.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16041018      PMCID: PMC1201206          DOI: 10.1128/IAI.73.8.5031-5038.2005

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  29 in total

1.  Safety and immunogenicity testing of an intranasal group B meningococcal native outer membrane vesicle vaccine in healthy volunteers.

Authors:  J J Drabick; B L Brandt; E E Moran; N B Saunders; D R Shoemaker; W D Zollinger
Journal:  Vaccine       Date:  1999-08-20       Impact factor: 3.641

2.  Immunogenicity and safety testing of a group B intranasal meningococcal native outer membrane vesicle vaccine.

Authors:  Rohit K Katial; Brenda L Brandt; Ellen E Moran; Stephen Marks; Victor Agnello; Wendell D Zollinger
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

3.  Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine.

Authors:  R B Belshe; W C Gruber; P M Mendelman; I Cho; K Reisinger; S L Block; J Wittes; D Iacuzio; P Piedra; J Treanor; J King; K Kotloff; D I Bernstein; F G Hayden; K Zangwill; L Yan; M Wolff
Journal:  J Pediatr       Date:  2000-02       Impact factor: 4.406

4.  Development and persistence of local and systemic antibody responses in adults given live attenuated or inactivated influenza A virus vaccine.

Authors:  M L Clements; B R Murphy
Journal:  J Clin Microbiol       Date:  1986-01       Impact factor: 5.948

5.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

6.  Isolation and characterization of a native cell wall complex from Neisseria meningitidis.

Authors:  W D Zollinger; D L Kasper; B J Veltri; M S Artenstein
Journal:  Infect Immun       Date:  1972-11       Impact factor: 3.441

Review 7.  Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, influenza vaccine live intranasal.

Authors: 
Journal:  Drugs R D       Date:  2003

8.  Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba.

Authors:  G V Sierra; H C Campa; N M Varcacel; I L Garcia; P L Izquierdo; P F Sotolongo; G V Casanueva; C O Rico; C R Rodriguez; M H Terry
Journal:  NIPH Ann       Date:  1991-12

9.  Human immunity to the meningococcus. II. Development of natural immunity.

Authors:  I Goldschneider; E C Gotschlich; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

10.  Human immunity to the meningococcus. I. The role of humoral antibodies.

Authors:  I Goldschneider; E C Gotschlich; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

View more
  3 in total

1.  Quantitative and qualitative preparations of bacterial outer membrane vesicles.

Authors:  Halima Chutkan; Ian Macdonald; Andrew Manning; Meta J Kuehn
Journal:  Methods Mol Biol       Date:  2013

Review 2.  Outer membrane vesicles: moving within the intricate labyrinth of assays that can predict risks of reactogenicity in humans.

Authors:  Omar Rossi; Francesco Citiulo; Francesca Mancini
Journal:  Hum Vaccin Immunother       Date:  2020-07-20       Impact factor: 3.452

3.  An Intranasal OMV-Based Vaccine Induces High Mucosal and Systemic Protecting Immunity Against a SARS-CoV-2 Infection.

Authors:  Peter A van der Ley; Afshin Zariri; Elly van Riet; Dinja Oosterhoff; Corine P Kruiswijk
Journal:  Front Immunol       Date:  2021-12-17       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.